Makerere University Walter Reed Project, Kampala, Uganda.
US Military Human Immunodeficiency Virus (HIV) Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Clin Infect Dis. 2022 Sep 10;75(4):657-664. doi: 10.1093/cid/ciab995.
Introduction of antiretroviral therapy (ART) has been associated with a decline in human immunodeficiency virus (HIV)-related mortality, although HIV remains a leading cause of death in sub-Saharan Africa. We describe all-cause mortality and its predictors in people living with HIV (PLWH) in the African Cohort Study (AFRICOS).
AFRICOS enrolls participants with or without HIV at 12 sites in Kenya, Uganda, Tanzania, and Nigeria. Evaluations every 6 months include sociobehavioral questionnaires, medical history, physical examination, and laboratory tests. Mortality data are collected from medical records and survivor interviews. Multivariable Cox proportional hazards models were used to calculate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for factors associated with mortality.
From 2013 through 2020, 2724 PLWH completed at least 1 follow-up visit or experienced death. Of these 58.4% were females, 25.8% were aged ≥ 50 years, and 98.3% were ART-experienced. We observed 11.42 deaths per 1000 person-years (95% CI: 9.53-13.68) with causes ascertained in 54% of participants. Deaths were caused by malignancy (28.1%), infections (29.7%), and other non-HIV related conditions. Predictors of mortality included CD4 ≤ 350 cells/µL (aHR 2.01 [95% CI: 1.31-3.08]), a log10copies/mL increase of viral load (aHR 1.36 [95% CI: 1.22-1.51]), recent fever (aHR 1.85[95% CI: 1.22-2.81]), body mass index < 18.5 kg/m2 (aHR 2.20 [95% CI: 1.44-3.38]), clinical depression (aHR 2.42 [95% CI: 1.40-4.18]), World Health Organization (WHO) stage III (aHR 2.18 [95% CI: 1.31-3.61]), a g/dL increase in hemoglobin (aHR 0.79 [95% CI: .72-.85]), and every year on ART (aHR 0.67 [95% CI: .56-.81]).
The mortality rate was low in this cohort of mostly virally suppressed PLWH. Patterns of deaths and identified predictors suggest multiple targets for interventions to reduce mortality.
抗逆转录病毒疗法(ART)的引入与人类免疫缺陷病毒(HIV)相关死亡率的下降有关,尽管 HIV 仍然是撒哈拉以南非洲地区的主要死亡原因。我们描述了非洲队列研究(AFRICOS)中 HIV 感染者(PLWH)的全因死亡率及其预测因素。
AFRICOS 在肯尼亚、乌干达、坦桑尼亚和尼日利亚的 12 个地点招募了有或没有 HIV 的参与者。每 6 个月进行一次评估,包括社会行为调查问卷、病史、体检和实验室检查。死亡率数据从病历和幸存者访谈中收集。多变量 Cox 比例风险模型用于计算与死亡率相关的因素的调整后危险比(aHR)和 95%置信区间(CI)。
2013 年至 2020 年,2724 名 PLWH 完成了至少 1 次随访或经历了死亡。其中 58.4%为女性,25.8%年龄≥50 岁,98.3%接受过 ART 治疗。我们观察到每 1000 人年有 11.42 人死亡(95%CI:9.53-13.68),在 54%的参与者中确定了死因。死亡原因包括恶性肿瘤(28.1%)、感染(29.7%)和其他非 HIV 相关疾病。死亡率的预测因素包括 CD4 细胞数≤350 个/μL(aHR 2.01[95%CI:1.31-3.08])、病毒载量 log10 拷贝/ml 增加(aHR 1.36[95%CI:1.22-1.51])、近期发热(aHR 1.85[95%CI:1.22-2.81])、体重指数(BMI)<18.5kg/m2(aHR 2.20[95%CI:1.44-3.38])、临床抑郁(aHR 2.42[95%CI:1.40-4.18])、世界卫生组织(WHO)分期 III 期(aHR 2.18[95%CI:1.31-3.61])、血红蛋白每增加 1g/dL(aHR 0.79[95%CI:0.72-0.85])和每接受 ART 治疗 1 年(aHR 0.67[95%CI:0.56-0.81])。
在这一队列中,大多数病毒受到抑制的 PLWH 的死亡率较低。死亡模式和确定的预测因素表明,有多个目标可以通过干预措施来降低死亡率。